SUMMARY
Hodgkin's disease (HD) is one of the malignant diseases with good chances for a cure. The prognosis for
cure depends on the initial stages and the outcome after initial treatment. Stages I or II at diagnosis, or a
complete remission after initial treatment are good indicators for the best prognosis to patients.
A frequent problem faced by clinicians is met at the post-therapy stage because of the difficulty of
distinguishing between dead tissue and disease activity in residual masses. Considering that these two
situations include therapy options that run from treatment abstention to autologous stem cell
transplantation, it is extremely important to distinguish them accurately.
Classical Tomography Scan (CT Scan), Gallium scintigraphy, Magnetic Resonance Imaging (MRI)
or Positron Emission Tomography (PET) are used to investigate residual masses. In order to clarify the
best way to confirm the post-treatment status of patients affected by HD, we describe in this paper our
experience of using PET to solve those problem situations where a CT Scan or MRI were not conclusive
and Gallium was negative.
KEY WORDS
PET; Hodgkin; residual
REFERENCES
Canellos GP: Residual mass in lymphoma may not
be residual disease. J Clin Oncol 6:931-933, 1988.
De Wit M, Bohuslavizki KH, Buchert R et al.:
(18)FDG-PET following treatment as valid
predictor for disease-free survival in Hodgkin's
lymphoma. Ann Oncol 12:29-37, 2001.
Glimelius I, Molin D, Amini RM et al.: Bulky
disease is the most important prognostic factor
in Hodgkin lymphoma stage IIB. Eur J
Haematol 71:327-333, 2003.
Hill M, Cunningham D, MacVicar D et al.: Role
of magnetic resonance imaging in predicting
relapse in residual masses after treatment of
lymphoma. J Clin Oncol 11:2273-2278, 1993.
Hoh CK, Glaspy J, Rosen P et al.: Whole-body
FDG-PET imaging for staging of Hodgkin's
disease and lymphoma. J Nucl Med 38:343-348, 1997.
Israel O, Front D, Lam M et al.: Gallium 67
imaging in monitoring lymphoma response to
treatment. Cancer 61:2439-2443, 1988.
Jerusalem G, Beguin Y, Fassotte MF et al.:
Whole-body positron emission tomography
using 18F-fluorodeoxyglucose for posttreatment
evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and
prognostic value than classical computed
tomography scan imaging. Blood 94:429-433, 1999.
Kostakoglu L, Yeh SD, Portlock C et al.
Validation of gallium-67-citrate single-photon
emission computed tomography in biopsy-confirmed
residual Hodgkin's disease in the
mediastinum. J Nucl Med 33:345-350, 1992.
Nyman R.S., Rehn S.M., Glimelius B.L. et al.:
Residual mediastinal masses in Hodgkin
disease: prediction of size with MR imaging.
Radiology 170:435-440, 1989.
Radford JA, Cowan RA, Flanagan M et al.: The
significance of residual mediastinal
abnormality on the chest radiograph following
treatment for Hodgkin's disease. J Clin Oncol
6:940-946, 1988.
Schaefer NG, Hany TF, Taverna C et al.: Non-
Hodgkin lymphoma and Hodgkin disease: co
registered FDG PET and CT at staging and
restaging-do we need contrast-enhanced CT?
Radiology 232:823-829, 2004.
Setoain FJ, Pons F, Herranz R et al.: Ga-67
scintigraphy for the evaluation of recurrences
and residual masses in patients with
lymphoma. Nucl Med Commun 18:405-411, 1997.
Weihrauch MR, Re D, Scheidhauer K et al.:
Thoracic positron emission tomography using
18F-fluorodeoxyglucose for the evaluation of
residual mediastinal Hodgkin disease. Blood
98:2930-2934, 2001.
Zinzani PL, Magagnoli M, Chierichetti F et al.:
The role of positron emission tomography
(PET) in the management of lymphoma
patients. Ann Oncol 10:1181-1184, 1999.
|
CITED
0
|
